Biosensor Market

According to Stratistics MRC, the Global Biosensor Market is accounted for $29.48 billion in 2023 and is expected to reach $57.44 billion by 2030 growing at a CAGR of 10.0% during the forecast period. Biosensors are medical devices that are used primarily to sense or detect the presence or concentration of biological material, such as a biomolecule or a bacterium. They are analytical tools that can transform a biological reaction into an electrical signal. Food and beverages, environmental monitoring, home care diagnostics, and other nanomechanical biosensors are just a few areas where biosensors are used.

According to the International Diabetic Federation, diabetes is rising at an annual rate of about 8.0 percent. More than 590 million people are expected to develop diabetes by 2035, implying that the market would increase rapidly throughout the projected period.



Market Dynamics:

Driver:

Extensive biosensor applications in medical fields

Biosensors have specialised criteria, which include that the prognosis of diseases and the survival of patients depend on an early and accurate disease diagnosis. Simple, disposable, user-friendly, and cost-effective devices with quick response times have become much more in demand in recent years. In laboratories, biosensors for self-testing, point-of-care testing, and glucose monitoring are being used and commercially developed. These biosensors measure glucose, urea, creatinine, lactate, and other substances using electrochemical and optical modes of transduction. Moreover, applications for biosensors can be found in many areas of the healthcare sector, including cancer, diabetes, and cardiovascular conditions. The use of biosensors for these diseases' early detection has increased as their prevalence around the globe has increased. Biosensors are ideal for new applications in hospitals, by patients at home, and by carers in non-hospital settings, thus boosting the use of biosensors.

Restraint:

High cost

The development, production, and implementation of biosensor technology involve complex processes, specialized materials, and advanced manufacturing techniques, driving up the overall cost. These expenses pose a barrier to widespread adoption, especially in resource-limited healthcare settings and industries sensitive to cost-efficiency. Affordability is crucial for broader accessibility and integration of biosensors into various applications, and efforts to mitigate costs through technological advancements and streamlined manufacturing processes are essential to overcoming this restraint and promoting market growth.

Opportunity:

Rising demand for biosensors in the pharmaceutical industry

Biosensors have a vital role in the pharmaceutical industry, contributing to drug development, monitoring, and quality control. During drug development, biosensors are employed to study the interactions between potential drug compounds and biological molecules, aiding in the identification and optimisation of drug candidates. In drug delivery systems, biosensors assist in optimising dosages and ensuring precise drug release, enhancing therapeutic outcomes. Quality control within the pharmaceutical industry heavily relies on biosensors for batch testing and validation. Biosensors can accurately detect and quantify specific biomolecules, ensuring the purity, potency, and stability of drugs. Thus, biosensors offer invaluable tools in the pharmaceutical sector, supporting drug discovery, development, and quality assurance, ultimately contributing to the advancement of healthcare and the improvement of patient outcomes.

Threat:

Data privacy concerns

Data privacy concerns present a significant restraint in the biosensor market. As biosensors collect and transmit sensitive health-related data, there's growing apprehension regarding data privacy and security. Users worry about potential misuse or unauthorised access to their personal health information, leading to reluctance to adopt biosensors, particularly wearables. Stricter data privacy regulations and increasing awareness of these concerns impact user trust and acceptance. Therefore, it is crucial to reduce concerns and promote a wider adoption of biosensors in healthcare and other industries by addressing these issues through effective data encryption, openness in data handling practices, and adherence to strict privacy legislation.

Covid-19 Impact

The COVID-19 epidemic had a huge impact on the world biosensor market. Numerous academic institutions and significant businesses have significantly raised their biosensor research and development in response to the COVID-19 epidemic. For instance, Jing Wang and his team at the Swiss Federal Laboratories for Materials Science and Technology and ETH Zurich have created a point-of-care biosensor that can specifically identify SARS-CoV-2, according to the American Association for the Advancement of Science (AAAS). The use of this sensor for clinical diagnosis and real-time monitoring of virus content in the air offers an alternative to traditional laboratory testing but does not replace it. Similarly, to create biosensors for COVID-19 testing, Rogue Valley Microdevices—a producer of microelectromechanical systems and sensors—is collaborating with early-stage companies like Cardea Bio & Hememics. Therefore, it is projected that these factors will spur market expansion throughout the forecast period.

The Embedded Device segment is expected to be the largest during the forecast period

The Embedded Device segment is estimated to hold the largest share, due to the significant surge in demand for embedded biosensors across multiple industries, such as healthcare, environmental monitoring, food and beverage, and consumer electronics. Embedded devices, a crucial subset of biosensors, involve the integration of biosensor technology into various systems, products, or platforms, enhancing their functionality and enabling real-time monitoring and analysis. Furthermore, these biosensors find applications in continuous glucose monitoring for diabetes management, wearable health trackers, environmental pollution monitoring, and smart packaging in the food industry, among others.

The Healthcare segment is expected to have the highest CAGR during the forecast period

The Healthcare segment is anticipated to have lucrative growth during the forecast period. The healthcare segment of the biosensors market is witnessing a transformative impact on patient care, disease management, and diagnostics. Biosensors have found extensive applications in glucose monitoring for diabetes, cardiac biomarker detection, pregnancy testing, infectious disease diagnosis, and drug-level monitoring. One of the significant advancements is the development of wearable biosensors, which facilitate continuous and non-invasive monitoring of vital signs, glucose levels, and other health parameters. In addition to this, these wearables provide valuable data to both patients and healthcare professionals, enabling proactive management of chronic conditions and timely interventions. With the potential to revolutionise healthcare delivery and improve patient outcomes, biosensors in the healthcare sector represent a vital and expanding market segment.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period, due to the region's vast population base and rising rates of various lifestyle disorders. Increasing demand for home healthcare, point-of-care services and other adult-focused healthcare enterprises in this region, as well as government initiatives to reduce hospital stays by developing outpatient care models. Regional statistics are also being fuelled by the launch of numerous health initiatives by national governments, the WHO, and organisations like Clinton Health Access Initiative, Inc. (CHAI). Additionally, the presence and availability of global brands and the challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the region data.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. Increased use of biosensors in this area for tracking food quality indicators is anticipated to support market growth. A rise in the market penetration of electronic medical records (EMR) and the development of miniaturised diagnostic equipment are predicted to drive market expansion over the forecasted period. In addition, the existence of the Clean Air Act, Clean Water Act, and National Environmental Policy Act in the U.S. is expected to open up opportunities for market expansion in North America. Moreover, the increase in demand for POC technologies in North America and the focus on rapid, simple, accurate, portable, and low-cost analytical instruments propel the market growth for the biosensors market in the region.



Key players in the market

Some of the key players in the Biosensor Market include Bio-rad Laboratories, Nova biomedical, Acon laboratories, Eastprint incorporated, SD biosensor, Medtronic, Universal Biosensors, Conductive technologies, F. Hoffmann-La Roche Ltd, Innovative Sensor Technology AG, Pinnacle Technology, Abbott Laboratories, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Biosensors International Group, Ltd, Dexcom, Inc., QTL Biosystems, Danaher Corporation, DuPont Biosensor Materials and Johnson & Johnson.

Key Developments:

In April 2023, Medtronic plc announced that the US FDA had approved its ‘MiniMed 780G’ system with the Guardian 4 sensor requiring no fingersticks while in SmartGuard technology. The system provides insulin to account for situations where users occasionally forget to bolus or underestimate the number of carbs in their meal. It has been approved for users of and above seven years of age with type 1 diabetes.

In March 2022, Nova Biomedical launched the Nova Max Pro Creatinine/eGFR Meter System, a tool for improving kidney care through kidney function screening and early kidney disease detection in POC settings outside the hospital, in all CE countries. The Nova Max Pro meter and creatinine biosensor measure blood creatinine and calculate estimated glomerular filtration rate (eGFR) from a 1.2 microliter capillary fingerstick blood sample in 30 seconds.

In January 2022, Roche and Sysmex signed a Global Business Partnership Agreement (GBP) to supply hematological diagnostic services. Using IT technology, the new cooperation aims to enhance clinical decision-making and consumer experience. This long-standing, fruitful collaboration is still going strong, offering hematological diagnostic improvements to labs all over the world.

Types Covered:
• Embedded Device
• Sensor Patch
• Other Types

Products Covered:
• Non-wearable Biosensors
• Wearable Biosensors

Technologies Covered:
• Electrochemical Biosensors
• Piezoelectric Biosensors
• Nanomechanical Biosensors
• Optical Biosensors
• Thermal Biosensors
• Other Technologies

Applications Covered:
• Medical Testing
• Drug discovery
• Food Toxicity
• Agricultural Testing
• Industrial Process
• Wastewater Treatment
• Healthcare
• Forensic and Biodefense
• Food & Beverages
• Point of care testing
• Research laboratories
• Other Applications

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances